Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports $17M in Revenues from Roche

NEW YORK, April 21 (GenomeWeb News) - CombiMatrix reported $17.6 million in revenues in the first quarter, with $17.3 million of that coming in recognition of deferred contract revenues from a research and development agreement with Roche.

 

CombiMatrix is the life sciences unit of Newport Beach, Calif., based Acacia Research, which issued its first-quarter financial report today, including results for its Mulkiteo, Wash.-based subsidiary that trades on the Nasdaq exchange under the symbol CBMX.

 

CombiMatrix said that it completed an R&D agreement with Roche that included the development of a microarray platform, the MatrixArray.

 

CombiMatrix's first-quarter receipts also included $217,000 in contract revenue from a $5.9 million contract with the US Department of Defense to develop a biowarfare detection technology. The company reported revenues of $216,000 in the first quarter of 2003.

 

CombiMatrix had a net income of $12 million for the quarter, compared to a loss of $5.1 million for the year-ago period.

 

The company spent $1.5 million on research and development in the period, compared to $2.3 million for the year-ago quarter.

 

Cash, cash equivalents, and short-term investments on hand totaled $18.4 million as of March 31, compared to $17.3 million as of Dec. 31.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.